Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of RALVIRINE 25 mg vs EDURANT 25 mg under fed conditions in healthy subjects
TCTR20210519006Phase 1Not yet recruiting
- Sponsor
- Government Pharmaceutical Organization
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rilpivirine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Government Pharmaceutical Organization. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
rilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on TCTR20210519006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210519006.